RetinalGenix Technologies (RTGN) Non-Current Debt (2022 - 2026)
RetinalGenix Technologies (RTGN) posted Non-Current Debt of $49000.0 for Q1 2026, little changed sequentially from $49000.0 in Q4 2025.
RetinalGenix Technologies (RTGN) Non-Current Debt (2022 - 2026) Analysis & Trends
RetinalGenix Technologies has reported Non-Current Debt for 4 years, with the latest figure at $49000.0 in Q1 2026.
- Quarterly Non-Current Debt changed N/A year-over-year to $49000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49000.0 (changed N/A YoY) and the FY2025 annual result came in at $49000.0, changed N/A from the prior year.
- Non-Current Debt steadied at $49000.0 in Q1 2026 per RTGN's latest filing, from $49000.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $49000.0 in Q4 2022 and troughed at $49000.0 in Q4 2022.
- A 4-year average of $49000.0 and a median of $49000.0 in 2022 frame the typical range for Non-Current Debt.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.20 Bn | 193.60 Bn | 7.27 Bn | 29.60 Bn |
| 2 | Stryker | 127.66 Bn | 124.19 Bn | 4.50 Bn | 14.19 Bn |
| 3 | Medtronic | 118.98 Bn | 109.76 Bn | 6.41 Bn | 26.17 Bn |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | 10.92 Bn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 598.70 Mn |
| 6 | Dexcom | 34.37 Bn | 32.42 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.89 Bn | 31.78 Bn | 2.18 Bn | 10.09 Bn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 7.34 Bn |
| 9 | Steris | 23.03 Bn | 22.55 Bn | 684.20 Mn | 1.65 Bn |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | 49,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49,000.00 |
| Dec 31, 2025 | 49,000.00 |
| Sep 30, 2023 | 49,000.00 |
| Dec 31, 2022 | 49,000.00 |